Chronic Kidney Disease-Induced Cardiac Fibrosis Is Ameliorated by Reducing Circulating Levels of a Non-Dialysable Uremic Toxin, Indoxyl Sulfate

• Suree Lekawanvijit,

  Affiliation Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

  ⨯
• Andrew R. Kompa,

  Affiliations Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, Department of Medicine, University of Melbourne, St. Vincent’s Hospital, Melbourne, Australia

  ⨯
• Minako Manabe,

  Affiliation Pharmaceutical Department, Kureha Corporation, Tokyo, Japan

  ⨯
• Bing H. Wang,

  Affiliation Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

  ⨯
• Robyn G. Langham,

  Affiliations Department of Medicine, University of Melbourne, St. Vincent’s Hospital, Melbourne, Australia, Department of Nephrology, St. Vincent’s Hospital, Melbourne, Australia

  ⨯
• Fuyuhiko Nishijima,

  Affiliation Pharmaceutical Department, Kureha Corporation, Tokyo, Japan

  ⨯
• Darren J. Kelly,

  Affiliation Department of Medicine, University of Melbourne, St. Vincent’s Hospital, Melbourne, Australia

  ⨯
• Henry Krum

  * E-mail: henry.krum@monash.edu

  Affiliation Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

  ⨯